DINESH

Sanofi Consumer Healthcare

Industry: Pharma B2C
Latest CMP 4,445
Today's Change ▼ -0.60%
52-Week High / Low 5,212 | 3,939
Price Date: 14-Aug-2026
Recommendation Buy
Target Price 6,306
Expected Upside 19.1%
Forecast Horizon 2 Years
Historical CAGR Not Available
1,000 Invested
Today's Value
Investment Period < 5 Years

Stock Snapshot

Post Results Return
-0.7%
Neutral Market Reaction
1-Year Target Price
5,716
2-Year Target Price
6,306
52-Week High / Low
5,212 / 3,939
20-Day Return
-1.9%
Market Cap (Cr.)
10,223
Current PE
45.0
P/BV Ratio
39.8
Dividend Yield
1.2%
Industry PE
38.6

Price Performance

Basis of our Recommendation

Sanofi Consumer Healthcare's recent management commentary highlights a stable revenue growth trajectory, supported by improving margins and a conservatively financed balance sheet. The company's focus on high-return products aligns with the broader industry trend of increasing pricing power and demand for innovative therapies. Vista's financial outlook anticipates continued revenue growth consistent with historical performance, alongside margin improvements driven by operational efficiencies. The favorable macroeconomic environment in India, characterized by contained inflation and strong liquidity, further supports this outlook. However, potential headwinds include rising input costs and competitive pressures from established players in the fragmented market. Over the next 12-24 months, key opportunities lie in leveraging the growing demand for biosimilars and innovative products, while watchpoints include maintaining margin stability amidst cost fluctuations and navigating the competitive landscape. Overall, Sanofi Consumer Healthcare is well-positioned for growth, with a target price reflecting a modest upside, reinforcing Vista's positive investment stance

👍 Why We Like This Stock

  • Management's focus on high-return products enhances revenue growth potential
  • Improving pricing power in the industry supports margin expansion
  • A conservatively financed balance sheet provides financial stability

Things To Watch Out For

  • Rising input costs may pressure margins in the near term
  • Intense competition in the fragmented market could impact market share
  • Potential currency fluctuations may affect export opportunities

Key Parameters

Balance Sheet Strength
Conservatively Financed
Market Share
Stable
Industry Outlook
Improving
Analyst View
Not Available
Dividend History
Consistent
FII Holdings
Stable

Financial Snapshot

Actuals Forecast
FY24 FY25 FY26 FY27 FY28
Revenue (Cr.) 555 724 878 938 1,062
Profit Before Tax (Cr.) 247 240 313 361 401
PBT Margin 44.6% 33.2% 3569.5% 38.5% 37.8%
Net Profit (Cr.) 185 172 233 269 299
Earnings Per Share 80.4 74.9 101.4 116.8 129.8

Analyst Recommendations

No analyst recommendations available.

Consensus Recommendation ► None
Consensus Target
Coverage 0 Analysts
Analysts' Viewpoint

Company Overview

Show Company Profile

Sanofi Consumer Healthcare India Limited operates as a fast-moving consumer healthcare company in India. The company offers products in the allergy, physical wellness, and pain care segments under Allegra, Combiflam, Avil, DePURA, Festal, and other brand names through distributors, wholesalers, government institutions and hospitals, pharmacy chains, and e-commerce platforms. The company was incorporated in 2023 and is based in Mumbai, India. Sanofi Consumer Healthcare India Limited operates as a subsidiary of Opella Healthcare Participations B.V.